CA2262086C - Use of a dehydroepiandrosterone derivative for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue - Google Patents
Use of a dehydroepiandrosterone derivative for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue Download PDFInfo
- Publication number
- CA2262086C CA2262086C CA002262086A CA2262086A CA2262086C CA 2262086 C CA2262086 C CA 2262086C CA 002262086 A CA002262086 A CA 002262086A CA 2262086 A CA2262086 A CA 2262086A CA 2262086 C CA2262086 C CA 2262086C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- halogen
- alkyl
- dhea
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical class C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 title claims abstract description 61
- 230000002708 enhancing effect Effects 0.000 title description 2
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 57
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical group C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 claims description 46
- 150000002367 halogens Chemical class 0.000 claims description 43
- 150000002148 esters Chemical class 0.000 claims description 25
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims description 20
- 150000002170 ethers Chemical class 0.000 claims description 20
- 229960002847 prasterone Drugs 0.000 claims description 20
- 150000007970 thio esters Chemical class 0.000 claims description 17
- 150000003568 thioethers Chemical class 0.000 claims description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 claims description 8
- 150000002485 inorganic esters Chemical class 0.000 claims description 8
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims description 4
- 230000003511 endothelial effect Effects 0.000 claims description 4
- 239000004593 Epoxy Substances 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000003700 epoxy group Chemical group 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 16
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 10
- MALIONKMKPITBV-UHFFFAOYSA-N 2-(3-chloro-4-hydroxyphenyl)-n-[2-(4-sulfamoylphenyl)ethyl]acetamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CCNC(=O)CC1=CC=C(O)C(Cl)=C1 MALIONKMKPITBV-UHFFFAOYSA-N 0.000 claims 1
- 229950009829 prasterone sulfate Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 26
- 210000000981 epithelium Anatomy 0.000 abstract description 14
- 208000014674 injury Diseases 0.000 abstract description 12
- 238000001356 surgical procedure Methods 0.000 abstract description 11
- 230000009089 cytolysis Effects 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 6
- 208000002847 Surgical Wound Diseases 0.000 abstract description 5
- 210000003038 endothelium Anatomy 0.000 abstract description 5
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 abstract description 4
- 208000002177 Cataract Diseases 0.000 abstract description 4
- 208000035874 Excoriation Diseases 0.000 abstract description 4
- 108010073385 Fibrin Proteins 0.000 abstract description 4
- 102000009123 Fibrin Human genes 0.000 abstract description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract description 4
- 206010038540 Renal tubular necrosis Diseases 0.000 abstract description 4
- 238000002399 angioplasty Methods 0.000 abstract description 4
- 210000004204 blood vessel Anatomy 0.000 abstract description 4
- 239000003518 caustics Substances 0.000 abstract description 4
- 210000004087 cornea Anatomy 0.000 abstract description 4
- 210000004351 coronary vessel Anatomy 0.000 abstract description 4
- 238000002651 drug therapy Methods 0.000 abstract description 4
- 229950003499 fibrin Drugs 0.000 abstract description 4
- 230000002496 gastric effect Effects 0.000 abstract description 4
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 4
- 210000000214 mouth Anatomy 0.000 abstract description 4
- 230000000241 respiratory effect Effects 0.000 abstract description 4
- 230000008733 trauma Effects 0.000 abstract description 4
- 210000005239 tubule Anatomy 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 description 82
- 206010052428 Wound Diseases 0.000 description 75
- 241000699670 Mus sp. Species 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 18
- 238000011282 treatment Methods 0.000 description 17
- 230000029663 wound healing Effects 0.000 description 17
- 125000000217 alkyl group Chemical group 0.000 description 14
- 125000005843 halogen group Chemical group 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 210000002919 epithelial cell Anatomy 0.000 description 13
- 241000282887 Suidae Species 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000033001 locomotion Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000008227 sterile water for injection Substances 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 206010015548 Euthanasia Diseases 0.000 description 4
- 208000034693 Laceration Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004731 jugular vein Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 102000005262 Sulfatase Human genes 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 210000000270 basal cell Anatomy 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 108060007951 sulfatase Proteins 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- 102000004896 Sulfotransferases Human genes 0.000 description 2
- 108090001033 Sulfotransferases Proteins 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 238000013310 pig model Methods 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- AAPOBCOILIIKTD-DGNOAVAJSA-N (3r,8r,9s,10r,13s,14s,16r)-3-bromo-16-methoxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1C=C2C[C@H](Br)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](OC)C(=O)[C@@]1(C)CC2 AAPOBCOILIIKTD-DGNOAVAJSA-N 0.000 description 1
- APEGMWQOSYXIKJ-ANXOIUTJSA-N (4s,8r,9s,10r,13s,14s,17r)-4,10,13-trimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound C1C[C@]2(C)[C@H](O)CC[C@H]2[C@@H]2CC=C3[C@H](C)C(O)CC[C@]3(C)[C@H]21 APEGMWQOSYXIKJ-ANXOIUTJSA-N 0.000 description 1
- CMWWRNHTVCSRPK-DPKMYYEESA-N (8S,9S,10R,13R,14S)-3-bromo-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,17-dodecahydrocyclopenta[a]phenanthren-16-one Chemical compound C[C@@]12CC(=O)C[C@H]1[C@@H]1CC=C3CC(Br)CC[C@]3(C)[C@H]1CC2 CMWWRNHTVCSRPK-DPKMYYEESA-N 0.000 description 1
- YGBMQSFYDTXMML-ORZNMBHWSA-N (8r,9s,10r,13s,14s)-10,13-dimethyl-16-methylidene-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C(C(=C)C4)=O)[C@@H]4[C@@H]3CC=C21 YGBMQSFYDTXMML-ORZNMBHWSA-N 0.000 description 1
- CRBHSKUAQFXQCO-HYHJSAQRSA-N (8r,9s,10r,13s,14s)-16-cyclobutyl-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCCCC3=CC2)C)CC[C@@]1(C1=O)C)C1C1CCC1 CRBHSKUAQFXQCO-HYHJSAQRSA-N 0.000 description 1
- FMGSKLZLMKYGDP-HQEMIIEJSA-N (8r,9s,10r,13s,14s)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1C(O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-HQEMIIEJSA-N 0.000 description 1
- FLCAHAJJOOEIKL-VIVDETTOSA-N (8r,9s,10r,13s,14s)-3-methoxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CCC(OC)C1 FLCAHAJJOOEIKL-VIVDETTOSA-N 0.000 description 1
- UUDDHRBLFHZVSX-UOIGCERHSA-N (8r,9s,10r,13s,14s,16r)-16-(dimethylamino)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1C=C2CC(O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](N(C)C)C(=O)[C@@]1(C)CC2 UUDDHRBLFHZVSX-UOIGCERHSA-N 0.000 description 1
- BDXUOHBGVSGPLE-MYBMVMQUSA-N (8s,9s,10r,13s,14s,17s)-3,10,13,17-tetramethyl-1,2,3,4,7,8,9,11,12,14,15,17-dodecahydrocyclopenta[a]phenanthren-16-one Chemical compound C1C=C2CC(C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=O)[C@@H](C)[C@@]1(C)CC2 BDXUOHBGVSGPLE-MYBMVMQUSA-N 0.000 description 1
- -1 16-oxymethylene-5-androsten-17-one Chemical class 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241001091551 Clio Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 241000408521 Lucida Species 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- HPFVBGJFAYZEBE-XNBTXCQYSA-N [(8r,9s,10r,13s,14s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3CC2)C)CC[C@@]11C)CC1OC(=O)CCC1CCCC1 HPFVBGJFAYZEBE-XNBTXCQYSA-N 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940094957 androgens and estrogen Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- BVGLIYRKPOITBQ-ANPZCEIESA-N benzylpenicillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 BVGLIYRKPOITBQ-ANPZCEIESA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000007387 excisional biopsy Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011850 initial investigation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- IWELAPXUKMGJIW-FAHSMDSGSA-N methyl (8r,9s,10r,13s,14s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-16-carboxylate Chemical compound C1C=C2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(C(=O)OC)C(=O)[C@@]1(C)CC2 IWELAPXUKMGJIW-FAHSMDSGSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000005122 simple epithelium Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000002544 sphingolipid group Chemical group 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- ZCUFMDLYAMJYST-UHFFFAOYSA-N thorium dioxide Chemical compound O=[Th]=O ZCUFMDLYAMJYST-UHFFFAOYSA-N 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/695,769 US5929060A (en) | 1992-05-01 | 1996-08-01 | Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue |
| US86917797A | 1997-06-05 | 1997-06-05 | |
| US08/695,769 | 1997-07-28 | ||
| US08/901,085 | 1997-07-28 | ||
| US08/901,085 US5922701A (en) | 1992-05-01 | 1997-07-28 | Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue |
| US08/869,177 | 1997-07-28 | ||
| PCT/US1997/012954 WO1998005338A2 (en) | 1996-08-01 | 1997-07-31 | Use of a dehydroepiandrosterone derivative for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2262086A1 CA2262086A1 (en) | 1998-02-12 |
| CA2262086C true CA2262086C (en) | 2003-11-11 |
Family
ID=27418624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002262086A Expired - Fee Related CA2262086C (en) | 1996-08-01 | 1997-07-31 | Use of a dehydroepiandrosterone derivative for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5922701A (es) |
| EP (1) | EP0915702B1 (es) |
| JP (1) | JP2002514168A (es) |
| AT (1) | ATE216242T1 (es) |
| AU (1) | AU713850B2 (es) |
| CA (1) | CA2262086C (es) |
| DE (1) | DE69712065T2 (es) |
| DK (1) | DK0915702T3 (es) |
| ES (1) | ES2174275T3 (es) |
| WO (1) | WO1998005338A2 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020091155A1 (en) * | 1995-06-22 | 2002-07-11 | Btg Pharmaceutical Corp. | Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1 |
| US6576659B1 (en) * | 1996-12-05 | 2003-06-10 | Bio-Technology General Corp. | Use of oxandrolone in the treatment of burns an other wounds |
| EP0908183A1 (en) * | 1997-10-08 | 1999-04-14 | Institute For Advanced Skin Research Inc. | Dehydroepiandrosterone or derivatives thereof for increasing the content of hyaluronic acid in skin |
| US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US20080015174A1 (en) * | 1998-11-24 | 2008-01-17 | Reading Christopher L | Metabolic Disease Treatments |
| CA2669753C (en) | 1999-09-30 | 2012-06-26 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment of androgen receptor driven conditions |
| FR2803750B1 (fr) * | 2000-01-17 | 2004-04-02 | Assist Publ Hopitaux De Paris | Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs biologiques et de ses derives metaboliques comme anti-atrophiant |
| EP2027816B1 (en) | 2000-07-19 | 2012-06-20 | Innovamédica S.A. de C.V. | Catheter for ischemic mucosal damage monitoring in hollow viscous organs |
| FR2831440B1 (fr) * | 2001-10-25 | 2003-12-26 | Oreal | Composition cosmetique, renfermant un derive de la dhea et un agent apaisant |
| US20040121991A1 (en) * | 2002-12-20 | 2004-06-24 | Araneo Barbara A. | Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers |
| WO2004089304A2 (en) * | 2003-04-01 | 2004-10-21 | Hollis-Eden Pharmaceuticals, Inc. | Antiandrogens with marginal agonist activity and methods of use |
| US20050026883A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| WO2006110172A2 (en) * | 2004-09-29 | 2006-10-19 | Hollis-Eden Pharmaceuticals.Inc. | Steroid analogs and characterization and treatment methods |
| US20060073099A1 (en) * | 2004-10-01 | 2006-04-06 | Frincke James M | Treatment screening methods |
| US8697152B2 (en) | 2005-08-31 | 2014-04-15 | Johnson & Johnson Consumer Companies, Inc. | Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract |
| US8758838B2 (en) | 2005-08-31 | 2014-06-24 | Johnson & Johnson Consumer Companies, Inc. | Anti-inflammatory compositions and methods of use |
| CN102215845A (zh) | 2008-04-03 | 2011-10-12 | 哈博生物科学公司 | 药学试剂的固体形式 |
| PL2300489T3 (pl) | 2008-06-06 | 2016-11-30 | Sposoby wytwarzania 17-alkinylo-7-hydroksysteroidów i związków pokrewnych | |
| EP4420666A4 (en) * | 2021-10-22 | 2025-12-10 | Univ Kyushu Nat Univ Corp | PHARMACEUTICAL COMPOSITION HAVING AN ANTI-CANCER IMMUNOSTIMULATING EFFECT AND/OR AN EFFECT OF POTENTIATING THE INHIBITION OF THE IMMUNE CHECKPOINT |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898694A (en) * | 1987-11-25 | 1990-02-06 | Schwartz Arthur G | 17-Hydroxy-steroids |
| US5001119A (en) * | 1987-11-25 | 1991-03-19 | Schwartz Arthur G | 16-substituted androstanes and 16-substituted androstenes |
| US5175154A (en) * | 1987-11-25 | 1992-12-29 | Research Corporation Technologies, Inc. | 5 α-pregnan-20-ones and 5-pregnen-20-ones and related compounds |
| US5110810A (en) * | 1991-02-08 | 1992-05-05 | Virginia Commonwealth University | Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of platelet aggregation |
| US5162198A (en) * | 1991-02-08 | 1992-11-10 | Virginia Commonwealth University | Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation |
| JPH07506372A (ja) * | 1992-05-01 | 1995-07-13 | ユニバーシティ・オブ・ユタ | インビボでのｉｌ−６産生を調節する組成物および方法 |
| US5686438A (en) * | 1993-03-09 | 1997-11-11 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| US5635496A (en) * | 1993-03-09 | 1997-06-03 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| CZ193495A3 (en) * | 1993-03-09 | 1996-04-17 | Univ Utah Res Found | The use of dehydroepiandrosterone derivatives for the preparation of a pharmaceutical preparation and pharmaceutical composition containing the derivative |
| US5587369A (en) * | 1993-03-09 | 1996-12-24 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| FR2729854A1 (fr) * | 1995-01-26 | 1996-08-02 | Oreal | Utilisation du sulfate de dehydroepi-androsterone dans une composition cosmetique ou dermatologique |
-
1997
- 1997-07-28 US US08/901,085 patent/US5922701A/en not_active Expired - Fee Related
- 1997-07-31 ES ES97936184T patent/ES2174275T3/es not_active Expired - Lifetime
- 1997-07-31 EP EP97936184A patent/EP0915702B1/en not_active Expired - Lifetime
- 1997-07-31 AT AT97936184T patent/ATE216242T1/de not_active IP Right Cessation
- 1997-07-31 CA CA002262086A patent/CA2262086C/en not_active Expired - Fee Related
- 1997-07-31 DE DE69712065T patent/DE69712065T2/de not_active Expired - Fee Related
- 1997-07-31 JP JP50797298A patent/JP2002514168A/ja not_active Ceased
- 1997-07-31 AU AU38917/97A patent/AU713850B2/en not_active Ceased
- 1997-07-31 DK DK97936184T patent/DK0915702T3/da active
- 1997-07-31 WO PCT/US1997/012954 patent/WO1998005338A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE69712065D1 (de) | 2002-05-23 |
| CA2262086A1 (en) | 1998-02-12 |
| WO1998005338A3 (en) | 1998-03-26 |
| AU3891797A (en) | 1998-02-25 |
| WO1998005338A2 (en) | 1998-02-12 |
| EP0915702B1 (en) | 2002-04-17 |
| US5922701A (en) | 1999-07-13 |
| EP0915702A2 (en) | 1999-05-19 |
| DK0915702T3 (da) | 2002-08-12 |
| DE69712065T2 (de) | 2002-11-07 |
| ATE216242T1 (de) | 2002-05-15 |
| AU713850B2 (en) | 1999-12-09 |
| ES2174275T3 (es) | 2002-11-01 |
| JP2002514168A (ja) | 2002-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2262086C (en) | Use of a dehydroepiandrosterone derivative for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue | |
| US5489581A (en) | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome | |
| US5686438A (en) | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome | |
| US5635496A (en) | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome | |
| AU736614B2 (en) | Method for reducing mast cell mediated allergic reactions | |
| US5811418A (en) | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome | |
| CA2380052C (en) | Nicotine receptor agonists in stem cell and progenitor cell recruitment | |
| AU2007281038B2 (en) | Methods and compositions for inhibiting angiogenesis | |
| EP0551182A1 (en) | Method of treating hyperproliferative vascular disease using rapamycin, eventually in combination with mycophenolic acid | |
| US5591740A (en) | Use of debromohymenialdisine for treating osteoarthritis | |
| JP2002502423A (ja) | 進行性組織壊死、再灌流損傷、細菌トランスロケーションおよび成人呼吸窮迫症候群の予防方法 | |
| WO2002049603A1 (en) | Compositions for prevention and alleviation of skin wrinkles | |
| US5929060A (en) | Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue | |
| JPH11124393A (ja) | 進行性組織壊死、再潅流損傷、細菌転座及び 成人呼吸困難症候群の予防法 | |
| IE890125L (en) | Growth inhibiting agent and the use thereof | |
| JPS63501718A (ja) | 哺乳動物の上皮性傷口の治癒をたかめる方法 | |
| JP2002504513A (ja) | 傷の治癒、火傷のショックの治療、アテローム性動脈硬化症、器官移植、鬱病、精神分裂病、及び化粧品におけるラムノリピドの使用 | |
| US5587369A (en) | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome | |
| KR102468374B1 (ko) | 덱스트란 또는 폴록사머를 포함하는 관절 질환 또는 결체조직 질환 치료용 조성물 | |
| JPH10147526A (ja) | 組織の上皮乃至は内皮の再形成を加速する方法 | |
| US5776921A (en) | Compositions for regulation of immune responses | |
| KR102316719B1 (ko) | 덱스트란 또는 폴록사머를 포함하는 관절 질환 또는 결체조직 질환 치료용 조성물 | |
| Jack et al. | Effect of decapitation on the development of insulin secretion in the foetal rabbit | |
| JP2000501698A (ja) | 尿膀胱疾患治療におけるｐｄｅ阻害剤の使用 | |
| Robinson | Differential effects of androgens on the morphlogy of guinea pig seminal vesicle epithelia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |